Drug name - Cubicin

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods Nov, 2030

(8 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL POWDER;INTRAVENOUS Discontinued
500MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.